Related Experiment Video
Updated: Aug 12, 2026
12:04
Microfluidic Picoliter Bioreactor for Microbial Single-cell Analysis: Fabrication, System Setup, and Operation
Published on: December 7, 2013
Plantibodies: applications, advantages and bottlenecks
Eva Stoger1, Markus Sack, Rainer Fischer
1Molecular Biotechnology Unit, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK. stoger@bbsrc.ac.uk
Current Opinion in Biotechnology
|April 16, 2002
Summary
Plants are being engineered as bioreactors to produce pharmaceutical antibodies for disease resistance and therapeutic applications. Recent advancements focus on optimizing expression and characterizing products, with early clinical trials showing promise for plant-derived antibodies.
Area of Science:
- Plant biotechnology
- Molecular farming
- Immunology
Background:
- Plants offer a scalable platform for producing complex pharmaceutical compounds.
- Engineering plants for antibody production addresses challenges in traditional manufacturing.
- Plant-specific post-translational modifications, like glycosylation, require careful consideration.
Purpose of the Study:
- To review strategies for utilizing plants as bioreactors for pharmaceutical antibody production.
- To highlight recent developments in plant-based expression systems and product characterization.
- To discuss the implications of plant-specific glycosylation on recombinant antibody function.
Main Methods:
- Review of current research and technological advancements in plant molecular farming.
- Analysis of strategies for antibody expression and engineering in plant systems.
- Examination of methods for characterizing plant-derived recombinant antibodies.
Main Results:
- Successful development of various strategies for producing pharmaceutical antibodies in plants.
- Focus on optimizing expression systems and detailed characterization of recombinant products.
- First plant-derived antibody products have successfully completed early-phase clinical trials.
Conclusions:
- Plants are a viable and advancing platform for the production of therapeutic antibodies.
- Further research into expression systems and glycosylation is crucial for product efficacy.
- Clinical trial success indicates the therapeutic potential of plant-made pharmaceuticals.
Related Concept Videos
01:09Recombinant DNA
Overview
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:27Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...